Compare Adaptive Biotechnologies Corp (ADPT) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bitdeer Technologies Group — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Bitdeer Technologies Group trades at $12.13 (market cap $3.13B). The key difference: Adaptive Biotechnologies Corp and Bitdeer Technologies Group are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ADPT | BTDR | |
|---|---|---|
Market Cap | $3.33B | $3.13B |
Sector | Health | Technology |
52-Week High | $22.37 | $25.90 |
52-Week Low | $10.24 | $7.28 |
Enterprise Value | $3.19B | $4.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BTDR trades at $14.25, up 2.89% today, with a bullish technical signal despite recent earnings misses. The company reported Q1 2026 revenue growth of 170% year-over-year to $188.9 million but posted a net loss. Analyst consensus is strongly bullish with an 81.82% buy rating and a $23.40 price target, suggesting significant upside. Recent developments include expansion into AI cloud infrastructure and new data center agreements in Norway and Canada.
The outlook for BTDR is mixed, with strong revenue growth and strategic AI expansion offset by persistent net losses and negative profit margins. Key risks include execution challenges in new ventures and sensitivity to Bitcoin market volatility. The stock presents a high-risk, high-reward opportunity, supported by Wall Street optimism but requiring careful monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
